Form 4: BioSig Technologies Director Acquires Shares in Lieu of Cash Compensation

Director Christopher Allen Baer acquired 23,345 shares of BioSig Technologies common stock in lieu of cash compensation for board fees.

Summary

• On April 24, 2025, Christopher Allen Baer, a director of BioSig Technologies, Inc., acquired 23,345 shares of common stock.
• The shares were granted under the company's 2023 Equity Incentive Plan in lieu of cash for Q4 2024 and Q1 2025 board fees.
• The shares were fully vested as of the date of grant, April 24, 2025.
• The acquisition price was $0 per share, based on a closing price of $0.84 per share on the date of grant.
• Following the transaction, Baer directly owns 103,345 shares of BioSig Technologies common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. A director taking shares in lieu of cash is neither overwhelmingly positive nor negative. It suggests a willingness to align with the company's performance, but could also indicate cash constraints.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• Using equity instead of cash preserves the company's cash reserves.

Industry Context

Directors receiving stock in lieu of cash compensation is a common practice, especially for smaller companies or those looking to conserve cash. It aligns the director's interests with those of the shareholders.

Comparison to Industry Standards

• Many small-cap and micro-cap companies use stock options and grants as part of their compensation packages for directors and executives.
• This practice is common in the biotech industry, where companies often have limited cash resources and rely on equity to attract and retain talent.
• Comparing BioSig's equity compensation practices to similar companies in the medical device sector would provide a more detailed benchmark.

Stakeholder Impact

• Shareholders: The transaction increases the director's stake in the company, aligning their interests with shareholders.
• Employees: The use of equity instead of cash may signal a need for financial prudence.

Key Dates

Keywords

BioSig Technologies, Director, Share Acquisition, Equity Incentive Plan, Christopher Allen Baer, BSGM, Form 4